Chiesi and Gossamer Bio enter into ink licensing agreement for PAH drug candidate


Chiesi and Gossamer Bio enter into ink licensing agreement for PAH drug candidate

Privately held Italian drugmaker Chiesi Farmaceutici announced a global collaboration and licensing agreement with U.S.-based Gossamer Bio (NASDAQ: GOSS) to develop and commercialize the latter’s seralutinib. Shares of San Diego-based Gossamer rose 3% to $0.72 in premarket trading on the news.

Chiesi said the global collaboration combines the strengths of both companies to support ongoing work in pulmonary hypertension…

This article can be read by registered users. If you want to continue reading, please register for free. With your one-week free trial, you’ll get access to exclusive features, interviews, reviews, and commentary from the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial has ended, you can subscribe here.

Try before you buy

• All the news driving pharmaceutical and biotech developments.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences journalists.
• Receive The Pharma Letter’s daily newsletter, free forever.

Become a subscriber

• Unrestricted access to the pharmaceutical and biotech industry’s leading news, commentary and analysis.
• The latest news on clinical trials, conferences, M&A, licensing, financing, regulatory, patents and legal, executive appointments, business strategy and financial performance.
• A daily roundup of important events in the pharmaceutical and biotech world.
• In-depth monthly briefings on board appointments and M&A news.
• Choose a cost-effective annual package or a flexible monthly subscription.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top